Barclays raised the firm’s price target on Janux Therapeutics (JANX) to $48 from $47 and keeps an Overweight rating on the shares following the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential
- Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements
- Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments
- Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc.
- Janux Therapeutics reports Q3 EPS (39c), consensus (61c)